(MENAFN- PR Newswire) Local
Altruix
pharmacies
will
fill
prescriptions
for
extended-release
buprenorphine
injection
for patients with moderate to severe opioid use disorder.
ANNAPOLIS, Md., Aug. 17, 2023 /PRNewswire/ -- Altruix,
a
leading
provider of
behavioral
health
pharmacy solutions, announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).
BRIXADI is an extended-release injection approved by the FDA to treat moderate to severe opioid
use
disorder
in
patients who
have
initiated
treatment
with
a
single
dose
of
a
transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine- containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.
"BRIXADI is another unique option to help the physicians we partner with to treat the growing threat of opioid use
disorder," says Eric
Elliott,
CEO,
Altruix.
"Patients struggling
with
opioid use disorder
are
at
risk
for
potentially
serious consequences,
including
long-term addiction
or
death. BRIXADI provides a noteworthy advancement in providing another option to treat opioid use disorder."
Clinical trials demonstrated BRIXADI's efficacy in reducing opioid use . It offers weekly and monthly
dosing
options for
patients
already receiving
buprenorphine
treatment.
It
is
obtained via a prescription and administered by a healthcare professional in a healthcare setting. Altruix partners with patients and prescribers to break down barriers such as prior authorizations and financial obstacles to help patients access BRIXADI.
Due to the risk of serious harm resulting from accidental intravenous (IV) administration, BRIXADI has a Boxed Warning and will be made available through a restricted distribution program called the
BRIXADI
Risk
Evaluation
and
Mitigation
Strategy (REMS).
Altruix
is
certified in this program and complies with all REMS requirements. Information on the BRIXADI REMS program will be available at .
About
Altruix
Altruix
is
a
high-touch
pharmacy
dedicated
to
behavioral
health and
intellectual
& developmental disability populations. The company's pharmacy expertise, optional Medherent technology, and special packaging promote medication adherence. Altruix provides value-added services that help clients take their medications as prescribed without having to juggle pill bottles, while physicians and staff spend less time managing medications, getting essential information, and
dealing with errors.
Altruix customers
achieve
improved outcomes
such
as
90%
adherence, 40% fewer dollars spent on ER and hospital visits. For more information, visit altruix.com .
SOURCE Altruix
Comments
No comment